Navigation Links
Tolerx Appoints Antonin de Fougerolles, Ph.D., as Chief Scientific Officer
Date:8/4/2010

CAMBRIDGE, Mass., Aug. 4 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the appointment of Antonin (Tony) de Fougerolles, Ph.D., as Chief Scientific Officer. Dr. de Fougerolles’ appointment as Tolerx’s CSO will provide leadership for the company’s research and early-stage product development programs involving novel therapies based on T cell modulation.  Dr. de Fougerolles brings to Tolerx more than 15 years of biotech R&D experience and expertise in immunology. He will direct the company’s R&D activities and strengthen Tolerx’s leadership in T cell immunology.

(Photo: http://photos.prnewswire.com/prnh/20100804/NE45601 )

(Photo: http://www.newscom.com/cgi-bin/prnh/20100804/NE45601 )

"We are delighted and enthusiastic about Tony joining us as CSO at this pivotal time, when Tolerx is poised to make substantial progress in expanding our pipeline of drug candidates based on T cell modulation," said Dr. Douglas J. Ringler, Chief Executive Officer of Tolerx. "Tony brings world-class R&D experience from well-known biotech companies, and his skills and expertise will extend our scientific leadership in T cell modulation and help lead Tolerx through our next stage of growth as we broaden our pipeline of innovative T cell therapies.”

Prior to joining Tolerx, Dr. de Fougerolles was Vice President, Research, Immunology, Metabolic, and Viral Disease at Alnylam Pharmaceuticals.  Dr. de Fougerolles joined Alnylam in 2003, holding positions of increasing responsibility and playing a key role in the development of several research programs, including those with Alnylam partners Novartis and Roche. Before joining Alnylam, he served as a Principal Scientist at Biogen, Inc. (now Biogen Idec Inc.), where he had worked since 1998. At Biogen, Dr. de Fougerolles worked on several immunology/inflammation-based programs and led research teams working to develop antibody-based therapeutics. Dr. de Fougerolles earned his Ph.D. in Immunology from Harvard University, and was a Research Fellow at the Laboratory of Molecular Biology in Cambridge, England.

“I am very excited to join Tolerx at this time of transformational growth, and believe the depth and quality of Tolerx’s team and expertise in T cell modulation position the company to significantly advance and build its pipeline of new therapeutics,” said Dr. de Fougerolles. “I am particularly enthusiastic about helping to advance the product pipeline and playing a key role in developing novel therapies that are on the cutting edge of exploiting the science of T cell activity to treat autoimmune diseases and cancer in fundamentally new ways."

About Tolerx

Tolerx, Inc., a world leader in the understanding of T cell function, is developing novel therapies intended to treat autoimmune diseases, diabetes, and cancer by specifically modulating T cell activity.  The company’s pipeline includes its lead candidate, otelixizumab, a targeted T cell immunomodulator in Phase 3 development for the treatment of type 1 diabetes that is partnered with GlaxoSmithKline.  TRX1, a Phase 1 candidate, is a nonlytic anti-CD4 antibody that is being developed for the treatment of aberrant or untoward humoral immune responses.  The company also has three pre-clinical candidates, TRX518, TRX585, and TRX385, that enhance immune responses and as such are being evaluated for potential benefit in the treatment of cancer and chronic infections. Tolerx is a privately held company headquartered in Cambridge, MA USA.  For more information, please visit www.tolerrx.com.


'/>"/>
SOURCE Tolerx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tolerx Initiates Confirmatory Phase 3 Clinical Trial, DEFEND-2, with Otelixizumab for Type 1 Diabetes
2. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
3. Tolerx Presents Preclinical Data on Novel T-cell Modulator, TRX518, for Antitumor Immune Response at Federation of Clinical Immunology Societies Scientific Meeting
4. Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
5. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
6. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
7. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
8. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
9. InQ Biosciences Appoints John Ryder as Senior Vice President, Sales & Marketing
10. Alexza Pharmaceuticals Appoints Joseph L. Turner to Its Board of Directors
11. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
Breaking Medicine News(10 mins):